Know Cancer

or
forgot password

PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients


N/A
18 Years
N/A
Not Enrolling
Male
Prostate Cancer, Obesity

Thank you

Trial Information

PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients


Inclusion Criteria:



- Histologically proven prostate cancer patients being on adjuvant Zoladex treatment
after primary therapy or on adjuvant therapy without primary curative therapy

Exclusion Criteria:

-Prostate cancer patients refractory to hormonal therapy, not agreeing to participate,
allergy against treatment

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy.

Outcome Time Frame:

Every 3 months

Safety Issue:

No

Principal Investigator

Istvan Buzogany

Investigator Role:

Principal Investigator

Investigator Affiliation:

Budapest City's Local Government "Péterfy Sándor" Hospital and Ambulatory Clinic

Authority:

Hungary: National Institute of Pharmacy

Study ID:

NIS-OHU-ZOL-2009/1

NCT ID:

NCT01020604

Start Date:

November 2009

Completion Date:

March 2013

Related Keywords:

  • Prostate Cancer
  • Obesity
  • BMI
  • Prostate cancer
  • Recurrence
  • Obesity
  • Prostatic Neoplasms

Name

Location